📇 Rhumatologue · VANDOEUVRE LES NANCY CEDEX · (54) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
33 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté
33ans d'exercice (thèse 1993)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Direction : JEAN DEVILLE
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)
2025ArticleJournal of Internal Medicine
Association of Cancer and Anti-Synthetase Syndrome: A Retrospective Multicenter Study
2025ArticleThe American Journal of Medicine
Inborn errors of immunity: Manifestation, treatment, and outcome—an ESID registry 1994–2024 report on 30,628 patients
2025ArticleJournal of Human Immunity
Exome‐based genotype‐first reverse phenotyping using structured electronic health record data identifies novel SERPINA1 variants associated with liver markers and demonstrates a dominant effect for specific variants on liver phenotype
2025ArticleHepatology Research
Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified
2025ArticleEClinicalMedicine
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin
2024ArticleAmerican Journal of Hematology
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
2024ArticleLa Revue de Médecine Interne
Long-term outcomes of childhood-onset systemic lupus erythematosus
2024ArticleRheumatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHRU NANCY - HOPITAUX DE BRABOIS
R DU MORVAN, 54511 VANDOEUVRE LES NANCY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of the rheumatic diseases · 2016
British journal of haematology · 2011
SummaryPatients with common variable immunodeficiency (CVID) are at high risk of developing immune thrombocytopenia (ITP) and/or autoimmune haemolytic anaemia (AHA). Given their underlying immunodeficiency, immunosuppressive treatment of these manifestations may increase the risk of infection. To assess efficacy and safety of rituximab in patients with CVID‐associated ITP/AHA, a multicentre retrospective study was performed. Thirty‐three patients, 29 adults and four children, were included. Patients received an average of 2·6 treatments prior to rituximab including steroids, intravenous immunoglobulin and splenectomy (21%). The median ITP/AHA duration at time of first rituximab administration was 12 months [range 1–324] and the indication for using rituximab was ITP (22 cases), AHA (n = 5) or both (n = 7); 1 patient was treated sequentially for ITP and then AHA. The overall initial response rate to rituximab was 85% including 74% complete responses. After a mean follow‐up of 39 ± 30 months after rituximab first administration, 10 of the initial responders relapsed and re‐treatment with rituximab was successful in 7/9. Severe infections occurred after rituximab in eight adults (24%), four of whom were not on immunoglobulin replacement therapy. In conclusion, rituximab appears to be highly effective and relatively safe for the management of CVID‐associated severe immune cytopenias.
Autoimmunity reviews · 2022
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Haematologica · 2025 · Journal Article
Rossignol J, Georgin-Lavialle S, Canioni D, Beganovic O, et al.
The American journal of medicine · 2025 · Journal Article
Bucy L, Devilliers H, Decker P, Manneville F, et al.
European journal of internal medicine · 2023 · Letter
Pontille F, Decker P, Gauchotte G, Jaussaud R, et al.
European journal of dermatology : EJD · 2022 · Journal Article
Tiotiu A, Jaussaud R
Frontiers in neurology · 2022 · Journal Article
Peultier-Celli L, Jaussaud R, Kaminsky P, Deibener-Kaminsky J, et al.
European journal of internal medicine · 2021 · Journal Article
Decker P, Moulinet T, Lopez B, Dubucquoi S, et al.
Clinical genetics · 2021 · Case Reports
El Chehadeh S, Legrand A, Stoetzel C, Geoffroy V, et al.
BMJ open · 2021 · Journal Article
Quilliot D, Gérard M, Bonsack O, Malgras A, et al.
Journal of hematology · 2019 · Journal Article
Serratrice C, Cherin P, Lidove O, Noel E, et al.
Molecular genetics and metabolism · 2018 · Journal Article
Fontaine M, Kim I, Dessein AF, Mention-Mulliez K, et al.
The American journal of medicine · 2017 · Case Reports
Dufrost V, Risse J, Malgras A, Barraud H, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2013 · Case Reports
Thiéfin G, Jaussaud R
Scandinavian journal of infectious diseases · 2012 · Journal Article
N'Guyen Y, Baumard S, Vernet-Garnier V, Batalla AS, et al.
Inflammatory bowel diseases · 2011 · Case Reports
N'Guyen Y, Baumard S, Salmon JH, Lemoine L, et al.
The Journal of rheumatology · 2011 · Journal Article
Foessel L, Besancenot JF, Blaison G, Magy-Bertrand N, et al.
Journal of internal medicine · 2026 · Journal Article
Billotte M, Moulinet T, Meyer A, Camara H, et al.
Rheumatology (Oxford, England) · 2026 · Journal Article
Sinnaeve A, Bader-Meunier B, Mirguet A, Moulinet T, et al.
The Journal of allergy and clinical immunology · 2024 · Journal Article
Polivka L, Madrange M, Bulai-Livideanu C, Barete S, et al.
Journal of clinical immunology · 2019 · Journal Article
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, et al.
Patient preference and adherence · 2017 · Journal Article
Pasquet M, Pellier I, Aladjidi N, Auvrignon A, et al.
The Journal of clinical endocrinology and metabolism · 2012 · Case Reports
Quentien MH, Delemer B, Papadimitriou DT, Souchon PF, et al.
Autoimmunity reviews · 2022 · Journal Article
Moriana C, Moulinet T, Jaussaud R, Decker P
Autoimmunity reviews · 2022 · Journal Article
Decker P, Moulinet T, Pontille F, Cravat M, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mirguet A, Aeschlimann FA, Lemelle I, Jaussaud R, et al.
Annales de dermatologie et de venereologie · 2018 · Journal Article
Garval E, Pennaforte JL, Jaussaud R, Servettaz A, et al.
British journal of haematology · 2011 · Journal Article
Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, et al.
Medicine · 2015 · Case Reports
Maestraggi Q, Bouattour M, Toquet S, Jaussaud R, et al.
Annals of the rheumatic diseases · 2016 · Journal Article
Hachulla E, Hatron PY, Carpentier P, Agard C, et al.
American journal of hematology · 2024 · Journal Article
Moraly J, Rossignol J, Rouzaud C, Gabas T, et al.
Autoimmunity reviews · 2022 · Journal Article
Moriana C, Moulinet T, Jaussaud R, Decker P
Medicine · 2015 · Journal Article
Deshayes S, Auboire L, Jaussaud R, Lidove O, et al.
Data from: Prevalence of Raynaud's phenomenon and nailfold capillaroscopic abnormalities in Fabry's disease: a cross-sectional study
[No description entered]
Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study
Abstract Background Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage diseases caused by defective enzyme activity involved in the catalysis of glycosaminoglycans. Published data on adult patients wi
Results of nailfold capillaroscopic parameters
Déficits immunitaires chez l'adulte et manifestation auto-immunes
Titre : Déficits immunitaires chez l'adulte et manifestation auto-immunes Intervenant : Pr Roland Jaussaud - Chef de service Médecine interne CHRU Nancy Soirée "Déficits immunitaires chez l'enfant et chez l'adulte" M
Pain and activity management in hypermobile Ehlers-Danlos syndrome: a lexicometric discourse analysis
Hypermobile Ehlers-Danlos syndrome (hEDS) is the most frequent hereditary connective tissue disorder. Its primary manifestations are tissue fragility, fatigue, and chronic pain, which result in significant functional imp
Demographic and clinical characteristics of Fabry patients and controls
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
RMD open · 2022 · Journal Article
Gottenberg JE, Chaudier A, Allenbach Y, Mekinian A, et al.
EClinicalMedicine · 2022 · Journal Article
Demotier S, Limelette A, Charmillon A, Baux E, et al.
European journal of internal medicine · 2022 · Journal Article
Decker P, Sobanski V, Moulinet T, Launay D, et al.
Magnesium research · 2020 · Clinical Trial
Quilliot D, Bonsack O, Jaussaud R, Mazur A
AIDS (London, England) · 2015 · Journal Article
Lambert D, Dramé M, Rouger C, Brodard V, et al.
Disability and rehabilitation · 2019 · Journal Article
Baeza-Velasco C, Bulbena A, Polanco-Carrasco R, Jaussaud R